Ventana Medical Systems, Inc. and Translational Genomics Research Institute (TGen) join forces to fight cancer

Two of Arizona’s premier biomedical institutions unite to develop critically needed diagnostic biomarkers for cancer

TUCSON, Ariz., June 25, 2013 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and the Translational Genomics Research Institute (TGen) today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer. The two Arizona-based institutions will leverage each other’s expertise in discovery and diagnostic product development, bringing innovative cancer diagnostic tests to patients.

The first project under the umbrella research agreement will focus on diagnostic, prognostic and drug biomarkers for pancreatic cancer, the fourth leading cause of death from cancer in the United States. This year, an estimated 45,000 people will be diagnosed and more than 38,000 patients will die from the disease. Worldwide, more than 213,000 are diagnosed with pancreatic cancer each year, and the numbers are growing. Fewer than 1 in 4 pancreatic cancer patients survive more than a year, and fewer than 6 percent survive more than five years — the worst survival rate of any cancer.

This dismal picture of pancreatic cancer is mainly due to the lack of tools for early detection and the ineffectiveness of current therapeutics. This is why new diagnostic markers and more efficacious
therapies are desperately needed.

“TGen is on the cutting edge of translational research, where investigators discover the genetic components of disease,” says Jeffrey Trent, Ph.D., President and Research Director of TGen. “Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today.”

“When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment,” says Ventana President and CEO Mara G. Aspinall. “As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to improve the lives of all patients afflicted with cancer. We are thrilled to be able to pursue this with a partner right in our Arizona backyard.”

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals.

Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies.

Visit www.ventana.com to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
E-mail: jacquie.bucher@ventana.roche.com

About the Translational Genomic Research Institute
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused
on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

TGen Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
E-mail: syozwiak@tgen.org